Coronavirus Vaccine, Russia, Vaccine, Central Russia

Coronavirus Vaccine, Russia

Russia aims to produce 'millions' of vaccine doses by 2021

Russia is pushing ahead with several vaccine prototypes, and one trialled by the Gamaleya institute in Moscow has reached advanced stages of development and is about to pass state registration.

4/8/2020 5:30:00 AM

Russia is pushing ahead with several vaccine prototypes, and one trialled by the Gamaleya institute in Moscow has reached advanced stages of development and is about to pass state registration.

Russia said Monday it aims to launch mass production of a coronavirus vaccine next month and turn out 'several million' doses per month by next year. The country is pushing ahead with several vaccine prototypes and one trialled by the Gamaleya institute in Moscow has reached advanced stages

The country is pushing ahead with several vaccine prototypes and one trialled by the Gamaleya institute in Moscow has reached advanced stages of development and is about to pass state registration, officials said."We are very much counting on starting mass production in September," Industry Minister Denis Manturov said in an interview published by state news agency TASS.

Singapore passports to be valid for 10 years for applications from October Exclusive: India holds up wireless approvals for China-made devices, delaying launches Sumitomo forecasts no profit from Myanmar telecom business in 2021/22

"We will be able to ensure production volumes of several hundred thousand a month, with an eventual increase to several million by the start of next year," he said, adding that one developer is preparing production technology at three locations in central Russia.

The head of the Russian Direct Investment Fund, which finances the trials, said he expects official registration of the vaccine to be complete"within ten days.""If this happens in the next ten days, we will be ahead not just of the United States but other countries too, it will be the first registered coronavirus vaccine," RDIF chief Kirill Dmitriev said in televised remarks. headtopics.com

Another vaccine, developed by Siberia-based Vektor lab, is currently undergoing clinical trials and two more will begin human testing within the next two months, Health Minister Mikhail Murashko said on Saturday.Gamaleya's vaccine is a so-called viral vector vaccine, meaning it employs another virus to carry the DNA encoding the needed immune response into cells.

Gamaleya's vaccine is based on the adenovirus, a similar technology to the coronavirus vaccine prototype developed by China's CanSino, currently in the advanced stage of clinical trials.- 'Who will buy it?' -The state-run Gamaleya institute came under fire after researchers and its director injected themselves with the prototype several months ago, with specialists criticising the move as an unorthodox and rushed way of starting human trials.

Vitaly Zverev, laboratory chief at the Mechnikov Research Institute of Vaccines and Sera, said it was too early to register a vaccine."I believe a vaccine that is not properly checked must not be registered, no matter in what country," he said.

"It is impossible to ensure the vaccine's safety in the time that has passed since the beginning of this pandemic," he told AFP."You can make anything, but who is going to buy it?"Zverev added that the three firms named as future producers of Russia's vaccines are well-known pharmaceutical firms that do not normally make vaccines, let alone high-tech ones using DNA technology. headtopics.com

Commentary: COVID-19 unlikely to become a thing of the past anytime soon India records 1.57 million new COVID-19 cases in a week Police warn of scam involving oxygen machines donation to India amid COVID-19 crisis

"No adenovirus-based vaccine has been proven effective before," he said."How are they going to grow it? Nobody explains this."Moscow has dismissed allegations from the UK, the United States and Canada that a hacking group linked to Russian intelligence services tried to steal information about a coronavirus vaccine from labs in the West.

Read more: Yahoo Singapore »

Not desirable to move ministers after less than a year, but situation ‘can’t be helped’: PM Lee

SINGAPORE — It is not desirable to give Cabinet ministers short stints in their portfolios owing to the disruption it can cause, but such moves are sometimes necessary, Prime Minister Lee Hsien Loong said on Friday (April 23).

Russia aims to produce 'millions' of COVID-19 vaccine doses by 2021 Russia said Monday it aims to launch mass production of a coronavirus vaccine next month and turn out 'several million' doses per month by next year.

Russia aims to produce 'millions' of virus doses by 2021MOSCOW (AFP) - Russia said on Monday (Aug 3) it aims to launch mass production of a coronavirus vaccine next month and turn out 'several million' doses per month by next year.. Read more at straitstimes.com.

Richard Branson to fly into space on a Virgin Galactic rocketship in early 2021MOJAVE, CALIFORNIA (REUTERS) - Billionaire Richard Branson will fly into space on a Virgin Galactic rocketship early next year, the space tourism company he founded said on Monday (Aug 3), adding that it would raise new funds with a share offering.. Read more at straitstimes.com.

Coronavirus: Tour de France start from Copenhagen delayed from 2021 to 2022, says mayorCOPENHAGEN (AFP) - The planned start of the Tour de France from Copenhagen, scheduled for 2021, has been pushed back to 2022 to avoid an overlap of sporting events disrupted by Covid-19, the city's mayor said Monday (Aug 3).. Read more at straitstimes.com.

Russia aims to produce 'millions' of COVID-19 vaccine doses by 2021 Russia said Monday it aims to launch mass production of a coronavirus vaccine next month and turn out 'several million' doses per month by next year.

Russia aims to produce 'millions' of virus doses by 2021MOSCOW (AFP) - Russia said on Monday (Aug 3) it aims to launch mass production of a coronavirus vaccine next month and turn out 'several million' doses per month by next year.. Read more at straitstimes.com.